

BEFORE THE  
MEDICAL BOARD OF CALIFORNIA  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA

In the Matter of the Accusation Against:

James Clyde Maclaren, Jr., M.D.

Physician's and Surgeon's  
Certificate No. G 48964

Case No.: 800-2017-029586

Respondent.


DECISION

The attached Stipulated Settlement is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.

This Decision shall become effective at 5:00 p.m. on November 18, 2021.

IT IS SO ORDERED: October 19, 2021.

MEDICAL BOARD OF CALIFORNIA



---

Richard E. Thorp, M.D. , Chair  
Panel B

1 ROB BONTA  
Attorney General of California  
2 STEVE DIEHL  
Supervising Deputy Attorney General  
3 MICHAEL C. BRUMMEL  
Deputy Attorney General  
4 State Bar No. 236116  
California Department of Justice  
5 2550 Mariposa Mall, Room 5090  
Fresno, CA 93721  
6 Telephone: (559) 705-2307  
Facsimile: (559) 445-5106  
7 E-mail: Michael.Brummel@doj.ca.gov  
*Attorneys for Complainant*

8  
9  
10 **BEFORE THE**  
**MEDICAL BOARD OF CALIFORNIA**  
**DEPARTMENT OF CONSUMER AFFAIRS**  
11 **STATE OF CALIFORNIA**  
12

13 In the Matter of the Accusation Against:

14 **JAMES CLYDE MACLAREN, JR., M.D.**  
15 **911 E. Tuolumne Rd.**  
**Turlock, CA 95382**

16 **Physician's and Surgeon's Certificate No. G**  
17 **48964**

18 Respondent.

Case No. 800-2017-029586

OAH No. 2020090617

**STIPULATED SETTLEMENT AND**  
**DISCIPLINARY ORDER**

19 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-  
20 entitled proceedings that the following matters are true:

21 **PARTIES**

22 1. William Prasifka (Complainant) is the Executive Director of the Medical Board of  
23 California (Board). He brought this action solely in his official capacity and is represented in this  
24 matter by Rob Bonta, Attorney General of the State of California, by Michael C. Brummel,  
25 Deputy Attorney General.

26 2. Respondent James Clyde Maclaren, Jr., M.D. (Respondent) is represented in this  
27 proceeding by attorney William M. White, whose address is: 7690 North Palm Avenue, Suite  
28 105, Fresno, California 93711.





1 **DISCIPLINARY ORDER**

2 IT IS HEREBY ORDERED that Physician's and Surgeon's Certificate No. G 48964 issued  
3 to Respondent James Clyde Maclaren, Jr., M.D. is revoked. However, the revocation is stayed  
4 and Respondent is placed on probation for three (3) years on the following terms and conditions:

5 1. EDUCATION COURSE. Within 60 calendar days of the effective date of this  
6 Decision, and on an annual basis thereafter, Respondent shall submit to the Board or its designee  
7 for its prior approval educational program(s) or course(s) which shall not be less than 40 hours  
8 per year, for each year of probation. The educational program(s) or course(s) shall be aimed at  
9 correcting any areas of deficient practice or knowledge and shall be Category I certified. The  
10 educational program(s) or course(s) shall be at Respondent's expense and shall be in addition to  
11 the Continuing Medical Education (CME) requirements for renewal of licensure. Following the  
12 completion of each course, the Board or its designee may administer an examination to test  
13 Respondent's knowledge of the course. Respondent shall provide proof of attendance for 65  
14 hours of CME of which 40 hours were in satisfaction of this condition.

15 2. PRESCRIBING PRACTICES COURSE. Within 60 calendar days of the effective  
16 date of this Decision, Respondent shall enroll in a course in prescribing practices approved in  
17 advance by the Board or its designee. Respondent shall provide the approved course provider  
18 with any information and documents that the approved course provider may deem pertinent.  
19 Respondent shall participate in and successfully complete the classroom component of the course  
20 not later than six (6) months after Respondent's initial enrollment. Respondent shall successfully  
21 complete any other component of the course within one (1) year of enrollment. The prescribing  
22 practices course shall be at Respondent's expense and shall be in addition to the Continuing  
23 Medical Education (CME) requirements for renewal of licensure.

24 A prescribing practices course taken after the acts that gave rise to the charges in the  
25 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board  
26 or its designee, be accepted towards the fulfillment of this condition if the course would have  
27 been approved by the Board or its designee had the course been taken after the effective date of  
28 this Decision.

1 Respondent shall submit a certification of successful completion to the Board or its  
2 designee not later than 15 calendar days after successfully completing the course, or not later than  
3 15 calendar days after the effective date of the Decision, whichever is later.

4 3. MEDICAL RECORD KEEPING COURSE. Within 60 calendar days of the effective  
5 date of this Decision, Respondent shall enroll in a course in medical record keeping approved in  
6 advance by the Board or its designee. Respondent shall provide the approved course provider  
7 with any information and documents that the approved course provider may deem pertinent.  
8 Respondent shall participate in and successfully complete the classroom component of the course  
9 not later than six (6) months after Respondent's initial enrollment. Respondent shall successfully  
10 complete any other component of the course within one (1) year of enrollment. The medical  
11 record keeping course shall be at Respondent's expense and shall be in addition to the Continuing  
12 Medical Education (CME) requirements for renewal of licensure.

13 A medical record keeping course taken after the acts that gave rise to the charges in the  
14 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board  
15 or its designee, be accepted towards the fulfillment of this condition if the course would have  
16 been approved by the Board or its designee had the course been taken after the effective date of  
17 this Decision.

18 Respondent shall submit a certification of successful completion to the Board or its  
19 designee not later than 15 calendar days after successfully completing the course, or not later than  
20 15 calendar days after the effective date of the Decision, whichever is later.

21 4. NOTIFICATION. Within seven (7) days of the effective date of this Decision, the  
22 Respondent shall provide a true copy of this Decision and Accusation to the Chief of Staff or the  
23 Chief Executive Officer at every hospital where privileges or membership are extended to  
24 Respondent, at any other facility where Respondent engages in the practice of medicine,  
25 including all physician and locum tenens registries or other similar agencies, and to the Chief  
26 Executive Officer at every insurance carrier which extends malpractice insurance coverage to  
27 Respondent. Respondent shall submit proof of compliance to the Board or its designee within 15  
28 calendar days.

1 This condition shall apply to any change(s) in hospitals, other facilities or insurance carrier.

2 5. SUPERVISION OF PHYSICIAN ASSISTANTS AND ADVANCED PRACTICE  
3 NURSES. During probation, Respondent is prohibited from supervising physician assistants and  
4 advanced practice nurses.

5 6. OBEY ALL LAWS. Respondent shall obey all federal, state and local laws, all rules  
6 governing the practice of medicine in California and remain in full compliance with any court  
7 ordered criminal probation, payments, and other orders.

8 7. QUARTERLY DECLARATIONS. Respondent shall submit quarterly declarations  
9 under penalty of perjury on forms provided by the Board, stating whether there has been  
10 compliance with all the conditions of probation.

11 Respondent shall submit quarterly declarations not later than 10 calendar days after the end  
12 of the preceding quarter.

13 8. GENERAL PROBATION REQUIREMENTS.

14 Compliance with Probation Unit

15 Respondent shall comply with the Board's probation unit.

16 Address Changes

17 Respondent shall, at all times, keep the Board informed of Respondent's business and  
18 residence addresses, email address (if available), and telephone number. Changes of such  
19 addresses shall be immediately communicated in writing to the Board or its designee. Under no  
20 circumstances shall a post office box serve as an address of record, except as allowed by Business  
21 and Professions Code section 2021, subdivision (b).

22 Place of Practice

23 Respondent shall not engage in the practice of medicine in Respondent's or patient's place  
24 of residence, unless the patient resides in a skilled nursing facility or other similar licensed  
25 facility.

26 License Renewal

27 Respondent shall maintain a current and renewed California physician's and surgeon's  
28 license.

1           Travel or Residence Outside California

2           Respondent shall immediately inform the Board or its designee, in writing, of travel to any  
3 areas outside the jurisdiction of California which lasts, or is contemplated to last, more than thirty  
4 (30) calendar days.

5           In the event Respondent should leave the State of California to reside or to practice  
6 ,Respondent shall notify the Board or its designee in writing 30 calendar days prior to the dates of  
7 departure and return.

8           9.    INTERVIEW WITH THE BOARD OR ITS DESIGNEE. Respondent shall be  
9 available in person upon request for interviews either at Respondent's place of business or at the  
10 probation unit office, with or without prior notice throughout the term of probation.

11           10. NON-PRACTICE WHILE ON PROBATION. Respondent shall notify the Board or  
12 its designee in writing within 15 calendar days of any periods of non-practice lasting more than  
13 30 calendar days and within 15 calendar days of Respondent's return to practice. Non-practice is  
14 defined as any period of time Respondent is not practicing medicine as defined in Business and  
15 Professions Code sections 2051 and 2052 for at least 40 hours in a calendar month in direct  
16 patient care, clinical activity or teaching, or other activity as approved by the Board. If  
17 Respondent resides in California and is considered to be in non-practice, Respondent shall  
18 comply with all terms and conditions of probation. All time spent in an intensive training  
19 program which has been approved by the Board or its designee shall not be considered non-  
20 practice and does not relieve Respondent from complying with all the terms and conditions of  
21 probation. Practicing medicine in another state of the United States or Federal jurisdiction while  
22 on probation with the medical licensing authority of that state or jurisdiction shall not be  
23 considered non-practice. A Board-ordered suspension of practice shall not be considered as a  
24 period of non-practice.

25           In the event Respondent's period of non-practice while on probation exceeds 18 calendar  
26 months, Respondent shall successfully complete the Federation of State Medical Boards' Special  
27 Purpose Examination, or, at the Board's discretion, a clinical competence assessment program  
28 that meets the criteria of Condition 18 of the current version of the Board's "Manual of Model



1 Disciplinary Orders and Disciplinary Guidelines” prior to resuming the practice of medicine.

2 Respondent’s period of non-practice while on probation shall not exceed two (2) years.

3 Periods of non-practice will not apply to the reduction of the probationary term.

4 Periods of non-practice for a Respondent residing outside of California will relieve  
5 Respondent of the responsibility to comply with the probationary terms and conditions with the  
6 exception of this condition and the following terms and conditions of probation: Obey All Laws;  
7 General Probation Requirements; Quarterly Declarations; Abstain from the Use of Alcohol and/or  
8 Controlled Substances; and Biological Fluid Testing..

9 11. COMPLETION OF PROBATION. Respondent shall comply with all financial  
10 obligations (e.g., restitution, probation costs) not later than 120 calendar days prior to the  
11 completion of probation. Upon successful completion of probation, Respondent’s certificate shall  
12 be fully restored.

13 12. VIOLATION OF PROBATION. Failure to fully comply with any term or condition  
14 of probation is a violation of probation. If Respondent violates probation in any respect, the  
15 Board, after giving Respondent notice and the opportunity to be heard, may revoke probation and  
16 carry out the disciplinary order that was stayed. If an Accusation, or Petition to Revoke Probation,  
17 or an Interim Suspension Order is filed against Respondent during probation, the Board shall have  
18 continuing jurisdiction until the matter is final, and the period of probation shall be extended until  
19 the matter is final.

20 13. LICENSE SURRENDER. Following the effective date of this Decision, if  
21 Respondent ceases practicing due to retirement or health reasons or is otherwise unable to satisfy  
22 the terms and conditions of probation, Respondent may request to surrender his or her license.  
23 The Board reserves the right to evaluate Respondent’s request and to exercise its discretion in  
24 determining whether or not to grant the request, or to take any other action deemed appropriate  
25 and reasonable under the circumstances. Upon formal acceptance of the surrender, Respondent  
26 shall within 15 calendar days deliver Respondent’s wallet and wall certificate to the Board or its  
27 designee and Respondent shall no longer practice medicine. Respondent will no longer be subject  
28 to the terms and conditions of probation. If Respondent re-applies for a medical license, the

1 application shall be treated as a petition for reinstatement of a revoked certificate.

2 14. PROBATION MONITORING COSTS. Respondent shall pay the costs associated  
3 with probation monitoring each and every year of probation, as designated by the Board, which  
4 may be adjusted on an annual basis. Such costs shall be payable to the Medical Board of  
5 California and delivered to the Board or its designee no later than January 31 of each calendar  
6 year.

7 15. FUTURE ADMISSIONS CLAUSE. If Respondent should ever apply or reapply for  
8 a new license or certification, or petition for reinstatement of a license, by any other health care  
9 licensing action agency in the State of California, all of the charges and allegations contained in  
10 Accusation No. 800-2017-029586 shall be deemed to be true, correct, and admitted by  
11 Respondent for the purpose of any Statement of Issues or any other proceeding seeking to deny or  
12 restrict license.

13 ///

14 ///

15 ///

16 ///

17 ///

18 ///

19 ///

20 ///

21 ///

22 ///

23 ///

24 ///

25 ///

26 ///

27 ///

28 ///

1 ACCEPTANCE

2 I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully  
3 discussed it with my attorney, William M. White. I understand the stipulation and the effect it  
4 will have on my Physician's and Surgeon's Certificate. I enter into this Stipulated Settlement and  
5 Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the  
6 Decision and Order of the Medical Board of California.

7  
8 DATED: 8/2/21 James Clyde MacLaren, Jr.  
9 JAMES CLYDE MACLAREN, JR., M.D.  
Respondent

10 I have read and fully discussed with Respondent James Clyde Maclaren, Jr., M.D. the terms  
11 and conditions and other matters contained in the above Stipulated Settlement and Disciplinary  
12 Order. I approve its form and content.

13 DATED: 8/2/21 William M. White  
14 WILLIAM M. WHITE  
Attorney for Respondent

15  
16 ENDORSEMENT

17 The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully  
18 submitted for consideration by the Medical Board of California.

19 DATED: \_\_\_\_\_

Respectfully submitted,

20  
21 ROB BONTA  
Attorney General of California  
22 STEVE DIEHL  
Supervising Deputy Attorney General

23  
24 MICHAEL C. BRUMMEL  
25 Deputy Attorney General  
26 Attorneys for Complainant

27 FR2019300834  
28 95395758

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**ACCEPTANCE**

I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully discussed it with my attorney, William M. White. I understand the stipulation and the effect it will have on my Physician's and Surgeon's Certificate. I enter into this Stipulated Settlement and Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the Medical Board of California.

DATED: \_\_\_\_\_  
JAMES CLYDE MACLAREN, JR., M.D.  
*Respondent*

I have read and fully discussed with Respondent James Clyde Maclaren, Jr., M.D. the terms and conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order. I approve its form and content.

DATED: \_\_\_\_\_  
WILLIAM M. WHITE  
*Attorney for Respondent*

**ENDORSEMENT**

The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Medical Board of California.

DATED: August 2, 2021

Respectfully submitted,  
ROB BONTA  
Attorney General of California  
STEVE DIEHL  
Supervising Deputy Attorney General



MICHAEL C. BRUMMEL  
Deputy Attorney General  
*Attorneys for Complainant*

FR2019300834  
95395758

**Exhibit A**

**Accusation No. 800-2017-029586**

1 XAVIER BECERRA  
Attorney General of California  
2 STEVE DIEHL  
Supervising Deputy Attorney General  
3 MICHAEL C. BRUMMEL  
Deputy Attorney General  
4 State Bar No. 236116  
California Department of Justice  
5 2550 Mariposa Mall, Room 5090  
Fresno, CA 93721  
6 Telephone: (559) 705-2307  
Facsimile: (559) 445-5106  
7 E-mail: Michael.Brummel@doj.ca.gov

8 *Attorneys for Complainant*

FILED  
STATE OF CALIFORNIA  
MEDICAL BOARD OF CALIFORNIA  
SACRAMENTO  
BY W. Francis Jan-23-20-20  
ANALYST

10 **BEFORE THE**  
11 **MEDICAL BOARD OF CALIFORNIA**  
12 **DEPARTMENT OF CONSUMER AFFAIRS**  
13 **STATE OF CALIFORNIA**

14 In the Matter of the Accusation Against:

Case No. 800-2017-029586

15 **James Clyde Maclaren, Jr., M.D.**  
16 **911 E. Tuolumne Rd.**  
**Turlock, CA 95382**

**ACCUSATION**

17 **Physician's and Surgeon's Certificate**  
18 **No. G 48964,**

19 Respondent.

20 **PARTIES**

21 1. Christine J. Lally (Complainant) brings this Accusation solely in her official capacity  
22 as the Interim Executive Director of the Medical Board of California, Department of Consumer  
23 Affairs (Board).

24 2. On or about September 27, 1982, the Medical Board issued Physician's and  
25 Surgeon's Certificate License No. G 48964 to James Clyde Maclaren, Jr., M.D. (Respondent).  
26 The Physician's and Surgeon's Certificate was in full force and effect at all times relevant to the  
27 charges brought herein and will expire on July 31, 2020, unless renewed.

28 ///

1 JURISDICTION

2 3. This Accusation is brought before the Board, under the authority of the following  
3 laws. All section references are to the Business and Professions Code (Code) unless otherwise  
4 indicated.

5 4. Section 2227 of the Code states:

6 (a) A licensee whose matter has been heard by an administrative law judge of  
7 the Medical Quality Hearing Panel as designated in Section 11371 of the Government  
8 Code, or whose default has been entered, and who is found guilty, or who has entered  
9 into a stipulation for disciplinary action with the board, may, in accordance with the  
10 provisions of this chapter:

11 (1) Have his or her license revoked upon order of the board.

12 (2) Have his or her right to practice suspended for a period not to exceed one  
13 year upon order of the board.

14 (3) Be placed on probation and be required to pay the costs of probation  
15 monitoring upon order of the board.

16 (4) Be publicly reprimanded by the board. The public reprimand may include a  
17 requirement that the licensee complete relevant educational courses approved by the  
18 board.

19 (5) Have any other action taken in relation to discipline as part of an order of  
20 probation, as the board or an administrative law judge may deem proper.

21 (b) Any matter heard pursuant to subdivision (a), except for warning letters,  
22 medical review or advisory conferences, professional competency examinations,  
23 continuing education activities, and cost reimbursement associated therewith that are  
24 agreed to with the board and successfully completed by the licensee, or other matters  
25 made confidential or privileged by existing law, is deemed public, and shall be made  
26 available to the public by the board pursuant to Section 803.1.

27 5. Section 2234 of the Code, states:

28 The board shall take action against any licensee who is charged with  
unprofessional conduct. In addition to other provisions of this article, unprofessional  
conduct includes, but is not limited to, the following:

(a) Violating or attempting to violate, directly or indirectly, assisting in or  
abetting the violation of, or conspiring to violate any provision of this chapter.

(b) Gross negligence.

(c) Repeated negligent acts. To be repeated, there must be two or more  
negligent acts or omissions. An initial negligent act or omission followed by a  
separate and distinct departure from the applicable standard of care shall constitute  
repeated negligent acts.

(1) An initial negligent diagnosis followed by an act or omission medically

1 appropriate for that negligent diagnosis of the patient shall constitute a single  
2 negligent act.

3 (2) When the standard of care requires a change in the diagnosis, act, or  
4 omission that constitutes the negligent act described in paragraph (1), including, but  
5 not limited to, a reevaluation of the diagnosis or a change in treatment, and the  
6 licensee's conduct departs from the applicable standard of care, each departure  
7 constitutes a separate and distinct breach of the standard of care.

8 (d) Incompetence.

9 (e) The commission of any act involving dishonesty or corruption which is  
10 substantially related to the qualifications, functions, or duties of a physician and  
11 surgeon.

12 (f) Any action or conduct which would have warranted the denial of a  
13 certificate.

14 (g) The practice of medicine from this state into another state or country  
15 without meeting the legal requirements of that state or country for the practice of  
16 medicine. Section 2314 shall not apply to this subdivision. This subdivision shall  
17 become operative upon the implementation of the proposed registration program  
18 described in Section 2052.5.

19 (h) The repeated failure by a certificate holder, in the absence of good cause, to  
20 attend and participate in an interview by the board. This subdivision shall only apply  
21 to a certificate holder who is the subject of an investigation by the board.

22 6. Section 2266 of the Code states: The failure of a physician and surgeon to maintain  
23 adequate and accurate records relating to the provision of services to their patients constitutes  
24 unprofessional conduct.

### 25 PERTINENT DRUGS AND DEFINITIONS

26 7. CURES. Controlled Substance Utilization Review and Evaluation System 2.0  
27 (CURES) is a database of Schedule II, III and IV controlled substance prescriptions dispensed in  
28 California serving the public health, regulatory and oversight agencies and law enforcement.  
CURES 2.0 is committed to the reduction of prescription drug abuse and diversion without  
affecting legitimate medical practice or patient care.

8. Controlled Substances Agreement, also known as a pain management contract or pain  
management agreement. A pain management agreement is recommended for patients on short-  
acting opioids at the time of the third visit; on long acting opioids; or expected to require more  
than three months of opioids. A pain management agreement outlines the responsibilities of the



1 physician and patient during the time that controlled substances are prescribed. See Medical  
2 Board of California: Guidelines for Prescribing Controlled Substances for Pain, November 2014.

3 9. Acetaminophen (Tylenol®) is a pain reliever and a fever reducer. It is used to treat  
4 many conditions including headache, muscle aches, arthritis, backache, toothaches, colds, and  
5 fevers. Acetaminophen is not a controlled substance.

6 10. Acetaminophen and hydrocodone bitartrate (Vicodin® and Norco®) is an opioid pain  
7 medication used for relief from moderate to moderately severe pain and has a high potential for  
8 abuse. Norco is a Schedule II controlled substance pursuant to Health and Safety Code section  
9 11055, subdivision (e), and a dangerous drug pursuant to Business and Professions Code section  
10 4022.

11 11. Acetaminophen and oxycodone (Endocet®, Percocet®, Roxicet®) is a combination  
12 of two medicines used to treat moderate to severe pain. Oxycodone is an opioid pain medication,  
13 commonly referred to as a narcotic. Acetaminophen is a less potent pain reliever that increases  
14 the effects of oxycodone. Oxycodone has a high potential for abuse. Oxycodone is a Schedule II  
15 controlled substance and narcotic as defined by section 11055, subdivision (b)(1) of the Health  
16 and Safety Code, and a Schedule II controlled substance as defined by Section 1308.12 (b)(1) of  
17 Title 21 of the code of Federal Regulations and a dangerous drug as defined in Business and  
18 Professions Code section 4022. Respiratory depression is the chief hazard from all opioid agonist  
19 preparations. Oxycodone should be used with caution and started in a reduced dosage (1/3 to 1/2  
20 of the usual dosage) in patients who are concurrently receiving other central nervous system  
21 depressants including sedatives or hypnotics, general anesthetics, phenothiazines, other  
22 tranquilizers and alcohol.

23 12. Baclofen is a muscle relaxant and antispasmodic agent used to treat muscle  
24 symptoms, such as spasm, pain, and stiffness. It is a dangerous drug pursuant to Business and  
25 Professions Code section 4022.

26 13. Benzodiazepines are a class of agents that work on the central nervous system, acting  
27 on select receptors in the brain that inhibit or reduce the activity of nerve cells within the brain.  
28 Valium, diazepam, alprazolam and temazepam are all examples of benzodiazepines. All

1 benzodiazepines are Schedule IV controlled substances and have the potential for abuse,  
2 addiction and diversion.

3 14. Cyclobenzaprine (Flexeril®) is a muscle relaxant that works by blocking nerve  
4 impulses that are sent to your brain. It is a dangerous drug pursuant to Business and Professions  
5 Code section 4022.

6 15. Diazepam (Valium®) is a Schedule IV controlled substance pursuant to Health and  
7 Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to Business and  
8 Professions Code section 4022. Diazepam is in the class of benzodiazepines.

9 16. Duloxetine (Cymbalta®) is a selective serotonin norepinephrine reuptake inhibitor  
10 antidepressant (SSNRI). It affects chemicals in the brain that may be unbalanced in people with  
11 depression. It is used to treat major depressive disorder, generalized anxiety disorder, and  
12 fibromyalgia. It is a dangerous drug pursuant to Business and Professions Code section 4022.

13 17. Gabapentin (Neurontin®) is an anti-epileptic drug, also called an anticonvulsant that  
14 affects chemicals and nerves in the body that are involved in the cause of seizures and some types  
15 of pain. It is used to treat neuropathic pain and seizures. It is a dangerous drug pursuant to  
16 Business and Professions Code section 4022.

17 18. Lorazepam (Ativan) is a benzodiazepine that affects chemicals in the brain that may  
18 be unbalanced in people with anxiety. It is a Schedule IV controlled substance pursuant to Health  
19 and Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to Business and  
20 Professions Code section 4022.

21 19. Methadone is an opioid medication that has a high potential for abuse. It is a  
22 dangerous drug as defined in section 4022 and a Schedule II controlled substance and narcotic as  
23 defined by section 11055 of the Health and Safety Code. Methadone is used as a pain reliever  
24 and as part of drug addiction detoxification and maintenance programs. It may cause a prolonged  
25 QT interval (a rare heart problem that may cause irregular heartbeat, fainting, or sudden death).

26 20. "MME" is an abbreviation for the Morphine Milligram Equivalents used to evaluate  
27 the levels of opioids prescribed to a patient. The Centers for Disease Control recommends  
28 avoiding or carefully justifying any dosage greater than 90 MME/day.

1           21. Oxycodone (Oxaydo®, OxyCONTIN®, Oxyfast®, Roxicodon®, Xtampza ER®) is a  
2 white odorless crystalline powder derived from an opium alkaloid. It is a pure agonist opioid  
3 whose principal therapeutic action is analgesia. Other therapeutic effects of oxycodone include  
4 anxiolysis, euphoria and feelings of relaxation. Oxycodone has a high potential for abuse.  
5 Oxycodone is a Schedule II controlled substance and narcotic as defined by section 11055,  
6 subdivision (b)(1) of the Health and Safety Code, and a Schedule II controlled substance as  
7 defined by Section 1308.12 (b)(1) of Title 21 of the code of Federal Regulations and a dangerous  
8 drug as defined in Business and Professions Code section 4022. Respiratory depression is the  
9 chief hazard from all opioid agonist preparations. Oxycodone should be used with caution and  
10 started in a reduced dosage (1/3 to 1/2 of the usual dosage) in patients who are concurrently  
11 receiving other central nervous system depressants including sedatives or hypnotics, general  
12 anesthetics, phenothiazines, other tranquilizers and alcohol.

13           22. Paroxetine (Paxil ®) is an antidepressant that belongs to a group of drugs called  
14 selective serotonin reuptake inhibitors. Paroxetine affects chemicals in the brain that may be  
15 unbalanced in people with depression, anxiety, or other disorders. It is used to treat depression,  
16 panic disorder, obsessive compulsive disorder, anxiety disorders, post-traumatic stress disorder,  
17 and premenstrual dysphoric disorder. It is a dangerous drug pursuant to Business and Professions  
18 Code section 4022.

19           23. Pregabalin (Lyrica®) is an antiepileptic drug, also called an anticonvulsant. It works  
20 by slowing down impulses in the brain that cause seizures. It also affects chemicals in the brain  
21 that send pain signals across the nervous system. It is a dangerous drug pursuant to Business and  
22 Professions Code section 4022. It is a Schedule V controlled substance and narcotic as defined  
23 by section 11058 of the Health and Safety Code, and a Schedule II controlled substance as  
24 defined by Section 1308.15 (e)(4) of Title 21 of the code of Federal Regulations and a dangerous  
25 drug as defined in Business and Professions Code section 4022.

26           24. Soma®, a brand name for carisoprodol, is a muscle relaxant with a known  
27 potentiating effect on narcotics. It is a muscle relaxer that works by blocking pain sensations  
28 between the nerves and the brain. In December 2011, the Federal Drug Administration listed

1 carisoprodol as a Schedule IV controlled substance (76 Fed.Reg. 77330 (Dec. 12, 2011).) Soma  
2 is also a dangerous drug pursuant to Business and Professions Code section 4022.

3 25. Tramadol (Ultram®) is a narcotic like pain reliever used to treat severe pain.  
4 Tramadol has the potential for abuse. Tramadol is a Schedule IV controlled substance pursuant to  
5 Health and Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to  
6 Business and Professions Code section 4022.

7 26. Xanax® (alprazolam) is in the class of benzodiazepine medications. It affects  
8 chemicals in the brain that may be unbalanced in people with anxiety. Xanax is used to treat  
9 anxiety disorders, panic disorders and anxiety caused by depression. Xanax has the potential for  
10 abuse. Xanax is a Schedule IV controlled substance pursuant to health and Safety Code section  
11 11057, subdivision (d), and a dangerous drug pursuant to Business and Professions Code section  
12 4022.

13 27. Zolpidem tartrate (Ambien®) is a Schedule IV controlled substance pursuant to  
14 Health and Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to  
15 Business and Professions Code section 4022. It is a sedative used to treat insomnia and has  
16 potential for abuse.

17 **FACTUAL ALLEGATIONS**

18 28. On or about May 23, 2019, Respondent participated in an interview with investigators  
19 working on behalf of the Board. Respondent explained that he currently practices family  
20 medicine, and that his only inpatient work is limited to newborns and hospice consults.  
21 Respondent stated that he is Board Certified in Family and Palliative Medicine. Respondent  
22 admitted that he was not utilizing pain management agreements in the treatment of his patients  
23 prior to learning of the Board's investigation. After learning of the Board's investigation,  
24 Respondent began using pain management agreements with patients. Respondent stated that he  
25 previously underestimated the importance of the Board's November 2014 Guidelines for  
26 Prescribing Controlled Substances for Pain.

27 \\\

28 \\\

1 CIRCUMSTANCES RELATED TO PATIENT A<sup>1</sup>

2 2014

3 29. During the period on or about February 13, 2014, through on or about December 19,  
4 2014, Patient A filled the following prescriptions for controlled substances:

5

Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2014-02-13	ZOLPIDEM TARTRATE	TER	12.5 MG	30	Respondent
2014-02-24	METHADONE HCL	TAB	5 MG	60	Respondent
2014-03-13	ZOLPIDEM TARTRATE	TER	12.5 MG	30	Respondent
2014-03-21	METHADONE HCL	TAB	5 MG	60	J.K.
2014-04-11	ZOLPIDEM TARTRATE	TER	12.5 MG	30	Respondent
2014-04-18	METHADONE HCL	TAB	5 MG	60	Respondent
2014-05-10	ZOLPIDEM TARTRATE	TER	12.5 MG	30	Respondent
2014-05-19	METHADONE HCL	TAB	5 MG	60	Respondent
2014-06-09	ZOLPIDEM TARTRATE	TER	12.5 MG	30	Respondent
2014-06-16	METHADONE HCL	TAB	5 MG	60	Respondent
2014-07-08	ZOLPIDEM TARTRATE	TER	12.5 MG	30	Respondent
2014-07-11	METHADONE HCL	TAB	5 MG	90	Respondent
2014-08-06	ZOLPIDEM TARTRATE	TER	12.5 MG	30	Respondent
2014-08-15	ALPRAZOLAM	TAB	0.25 MG	60	Respondent
2014-08-25	METHADONE HCL	TAB	5 MG	90	Respondent
2014-09-02	ZOLPIDEM TARTRATE	TER	12.5 MG	30	Respondent
2014-09-15	ALPRAZOLAM	TAB	0.25 MG	60	Respondent
2014-09-22	METHADONE HCL	TAB	5 MG	90	Respondent
2014-09-30	ZOLPIDEM TARTRATE	TER	12.5 MG	30	Respondent
2014-10-17	ALPRAZOLAM	TAB	0.25 MG	60	Respondent
2014-10-22	METHADONE HCL	TAB	5 MG	90	Respondent
2014-11-03	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2014-11-18	ALPRAZOLAM	TAB	0.25 MG	60	Respondent
2014-11-20	METHADONE HCL	TAB	5 MG	90	Respondent
2014-12-05	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2014-12-16	ALPRAZOLAM	TAB	0.25 MG	60	Respondent
2014-12-19	METHADONE HCL	TAB	5 MG	90	Respondent

6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

23 2015

24 30. On or about March 10, 2015, Patient A presented to Respondent at 62 years of age for  
25 a follow up visit related to his complaints of anxiety and lower back pain. Respondent noted that  
26 Patient A was requesting additional pain and anxiety medications for his conditions. Respondent  
27 documented a cursory examination, which revealed no abnormal findings. In the History of

28 <sup>1</sup> To protect the privacy of patients, individual names are not identified in this Accusation.

1 Present Illness section of the medical records, Respondent noted that Patient A's lower back pain  
2 was stable. Respondent documented a nonfocal neurological examination, but did not document  
3 any objective findings related to the diagnosis of low back pain. Respondent did not document an  
4 adequate informed consent, treatment plan, physical examination or objectives for Patient A's  
5 low back pain and continued use of controlled substances. Respondent's plan for Patient A was  
6 to prescribe Xanax and methadone. In an interview with investigators, Respondent stated that he  
7 did not know if Patient A was still working at the time of the March 10, 2015 visit. Respondent  
8 admitted that he didn't document any information relating to Patient A's anxiety during the  
9 encounter, but assumed that Patient A must have been anxious since he was being treated for  
10 anxiety.

11 31. On or about July 1, 2015, Patient A returned to Respondent for refills on his  
12 medications and complaining of low back pain, and chest pain. Respondent noted that Patient  
13 A's heart rate was rapid and ordered a stress test. Respondent documented a nonfocal  
14 neurological examination, but did not document any objective findings related to the diagnosis of  
15 low back pain. Respondent did not document an adequate informed consent, treatment plan,  
16 physical examination or objectives for Patient A's low back pain and continued use of controlled  
17 substances.

18 32. On or about November 19, 2015, Patient A returned to Respondent following a  
19 transition of care from a recent inpatient hospital stay. Patient A reported that his back pain was  
20 worse, and gabapentin was not helpful in relieving his pain. Patient A reported that he "wants  
21 more pain medication..." Respondent did not document any information related to Patient A's  
22 continued use of Xanax and methadone. Respondent documented a nonfocal neurological  
23 examination, but did not document any objective findings related to the diagnosis of low back  
24 pain. Respondent did not document an adequate informed consent, treatment plan, physical  
25 examination or objectives for Patient A's low back pain and continued use of controlled  
26 substances. Respondent's plan for Patient A was to prescribe Cymbalta.

27 33. On or about December 5, 2015, Respondent ordered that Patient A undergo a urine  
28 drug screen. Patient A tested positive for benzodiazepines and opiates.

1 34. Patient A returned to Respondent for appointments to refill his medications  
 2 approximately three times in 2015. Respondent's medical records for Patient A typically  
 3 identified the chief complaint as "this is a follow-up visit," and the plan was to refill medications.  
 4 Respondent did not document a treatment plan, informed consent, physical examination or pain  
 5 management agreement.

6 35. During the period on or about January 5, 2015, through on or about December 30,  
 7 2015, Patient A filled the following prescriptions for controlled substances:

Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2015-01-05	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2015-01-15	METHADONE HCL	TAB	5 MG	90	Respondent
2015-01-16	ALPRAZOLAM	TAB	0.25 MG	60	Respondent
2015-02-03	ZOLPIDEM TARTRATE	TAB	10 MG	5	Respondent
2015-02-04	ZOLPIDEM TARTRATE	TAB	10 MG	25	Respondent
2015-02-12	METHADONE HCL	TAB	5 MG	90	Respondent
2015-02-14	ALPRAZOLAM	TAB	0.25 MG	60	Respondent
2015-02-28	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2015-03-10	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2015-03-11	METHADONE HCL	TAB	5 MG	90	Respondent
2015-03-29	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2015-04-09	METHADONE HCL	TAB	5 MG	90	Respondent
2015-04-09	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2015-04-23	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2015-05-07	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2015-05-09	METHADONE HCL	TAB	5 MG	90	Respondent
2015-05-17	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2015-06-01	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2015-06-06	METHADONE HCL	TAB	5 MG	90	Respondent
2015-06-17	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2015-07-01	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2015-07-04	METHADONE HCL	TAB	5 MG	90	Respondent
2015-07-10	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2015-07-26	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2015-08-01	METHADONE HCL	TAB	5 MG	90	Respondent
2015-08-08	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2015-08-25	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2015-08-30	METHADONE HCL	TAB	5 MG	90	Respondent
2015-09-09	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2015-09-24	ALPRAZOLAM	TAB	0.5 MG	60	Respondent

Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2015-09-29	METHADONE HCL	TAB	5 MG	90	Respondent
2015-10-08	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2015-10-24	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2015-10-29	METHADONE HCL	TAB	5 MG	90	Respondent
2015-11-02	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2015-11-23	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2015-11-28	METHADONE HCL	TAB	5 MG	90	Respondent
2015-11-29	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2015-12-22	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2015-12-28	METHADONE HCL	TAB	5 MG	90	J.K.
2015-12-30	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent

2016

36. Patient A returned to Respondent for appointments to refill his medications approximately three times in 2016. Respondent's medical records for Patient A typically identified the chief complaint as "this is a follow-up visit," and the plan was to refill medications. Respondent did not document a treatment plan, informed consent, physical examination or pain management agreement.

37. On or about February 24, 2016, Patient A returned to Respondent for refills of his medications. Respondent noted that Patient A's low back pain was stable, and that he was frequently suffering from anxiety. Respondent documented a nonfocal neurological examination, but did not document any objective findings related to the diagnosis of low back pain. Respondent did not document an adequate informed consent, treatment plan, physical examination or objectives for Patient A's low back pain and continued use of controlled substances. Respondent continued to prescribe Xanax, methadone and Ambien, and provided a new prescription for Prozac, with one refill. During an interview with investigators, Respondent admitted that he did not perform a thorough examination on Patient A's back during this visit, despite continuing to prescribe him methadone for pain. Respondent stated that he has since changed his practice, and today he would normally conduct a thorough examination of Patient A's back at a similar visit related to the prescribing of controlled substances.

38. On or about May 23, 2016, Patient A returned to Respondent for a follow up visit. Respondent noted that Patient A's back pain was worse and required a higher dose of methadone,



1 but failed to document an adequate physical examination related to Patient A's back pain.  
2 Respondent's only documentation of a physical examination consisted of recording Patient A's  
3 vital signs. Respondent did not document an adequate informed consent, treatment plan, physical  
4 examination or objectives for Patient A's low back pain and continued use of controlled  
5 substances. Respondent's plan for Patient A was to refill his prescriptions of methadone and  
6 provide samples of Lyrica.

7 39. On or about June 18, 2016, Patient A was admitted to the hospital after an apparent  
8 suicide attempt. Patient A presented with a history of "chronic pain and prescription drug abuse"  
9 after making a suicidal gesture to his friends and stating that he was going to kill himself. Patient  
10 A's family reported that he had previously suffered from an accidental overdose. His discharge  
11 diagnosis included major depressive disorder, and history of prescription drug abuse.

12 40. On or about November 17, 2016, Patient A returned to Respondent seeking refills of  
13 his methadone. Respondent noted that Patient A's back pain was stable, but failed to document  
14 an adequate physical examination related to Patient A's back pain. Respondent did not document  
15 an adequate informed consent, treatment plan, physical examination or objectives for Patient A's  
16 low back pain and continued use of controlled substances. Respondent documented a nonfocal  
17 neurological examination, but did not document any objective findings related to the diagnosis of  
18 low back pain. Respondent's plan for Patient A was to refill his prescriptions of methadone and  
19 Xanax.

20 41. During the period on or about January 5, 2016, through on or about December 28,  
21 2016, Patient A filled the following prescriptions for controlled substances:

Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2016-01-19	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2016-01-25	METHADONE HCL	TAB	5 MG	90	Respondent
2016-01-27	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2016-02-21	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2016-02-24	METHADONE HCL	TAB	5 MG	90	Respondent
2016-02-24	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2016-03-01	HYDROCODONE BITARTRATE- ACETAMINOPHEN	TAB	325 MG-5 MG	20	S.Y.
2016-03-21	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent

Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2016-03-21	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2016-03-25	METHADONE HCL	TAB	5 MG	90	Respondent
2016-04-18	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2016-04-18	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2016-04-24	METHADONE HCL	TAB	5 MG	90	Respondent
2016-05-15	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2016-05-15	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2016-05-23	METHADONE HCL	TAB	5 MG	90	Respondent
2016-06-13	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2016-06-15	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2016-06-21	METHADONE HCL	TAB	5 MG	90	Respondent
2016-07-14	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2016-07-14	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2016-07-21	METHADONE HCL	TAB	5 MG	90	Respondent
2016-08-07	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2016-08-12	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2016-08-17	METHADONE HCL	TAB	5 MG	90	Respondent
2016-09-07	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2016-09-10	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2016-09-10	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2016-09-13	METHADONE HCL	TAB	5 MG	90	Respondent
2016-10-07	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2016-10-07	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2016-10-10	METHADONE HCL	TAB	5 MG	90	Respondent
2016-11-04	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2016-11-04	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2016-11-08	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2016-11-09	METHADONE HCL	TAB	5 MG	90	Respondent
2016-11-22	ALPRAZOLAM	TAB	0.5 MG	90	Respondent
2016-12-01	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2016-12-05	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2016-12-09	METHADONE HCL	TAB	5 MG	90	Respondent
2016-12-21	ALPRAZOLAM	TAB	0.5 MG	90	Respondent
2016-12-28	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent

2017

42. Patient A returned to Respondent for appointments to refill his medications approximately three times in 2017. Respondent's medical records for Patient A typically identified the chief complaint as "this is a follow-up visit," with the exception of a note dated August 17, 2017, which listed only a series of existing medical problems. The typical plan for

1 Patient A was to refill his medications. Respondent did not document a treatment plan, informed  
2 consent, physical examination or pain management agreement. Respondent continued to refill  
3 Patient A's medications, but did not document any new information relating to Patient A's pain  
4 symptoms.

5 43. On or about March 27, 2017, Patient A returned to Respondent seeking refills of his  
6 methadone. Respondent noted that Patient A's back pain was stable, but failed to document an  
7 adequate physical examination related to Patient A's back pain. Respondent did not document an  
8 adequate informed consent, treatment plan, physical examination or objectives for Patient A's  
9 low back pain and continued use of controlled substances. Respondent documented a nonfocal  
10 neurological examination, but did not document any objective findings related to the diagnosis of  
11 low back pain. Respondent's plan for Patient A was to refill his prescriptions of methadone and  
12 Xanax.

13 44. On or about August 1, 2017, Patient A returned to Respondent seeking refills of his  
14 methadone. Respondent's only documentation of a physical examination consisted of recording  
15 Patient A's vital signs. Respondent did not document an adequate informed consent, treatment  
16 plan, physical examination or objectives for Patient A's low back pain and continued use of  
17 controlled substances. Respondent's plan for Patient A was to refill his prescriptions of  
18 methadone and Xanax.

19 45. During the period on or about January 1, 2017, through on or about March 23, 2017,  
20 Patient A filled the following prescriptions for controlled substances:

Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2017-01-01	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2017-01-08	METHADONE HCL	TAB	5 MG	90	Respondent
2017-01-22	ALPRAZOLAM	TAB	0.5 MG	90	Respondent
2017-01-28	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2017-02-06	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2017-02-09	METHADONE HCL	TAB	5 MG	90	Respondent
2017-02-23	ALPRAZOLAM	TAB	0.5 MG	90	Respondent
2017-03-02	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2017-03-06	METHADONE HCL	TAB	5 MG	90	Respondent
2017-03-23	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent

28 ///

2018

46. During the period on or about May 7, 2018, through on or about December 6, 2018,

Patient A filled the following prescriptions for controlled substances:

Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2018-05-07	METHADONE HCL	TAB	5 MG	90	Respondent
2018-07-06	METHADONE HCL	TAB	5 MG	90	Respondent
2018-09-04	METHADONE HCL	TAB	5 MG	90	Respondent
2018-10-04	METHADONE HCL	TAB	5 MG	90	Respondent
2018-10-10	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2018-10-10	ALPRAZOLAM	TAB	0.5 MG	90	Respondent
2018-11-03	METHADONE HCL	TAB	5 MG	90	Respondent
2018-11-08	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2018-12-03	METHADONE HCL	TAB	5 MG	90	Respondent
2018-12-06	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent

2019

47. During the period on or about January 2, 2019, through on or about December 3,

2019, Patient A filled the following prescriptions for controlled substances:

Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2019-01-02	METHADONE HCL	TAB	5 MG	90	Respondent
2019-01-04	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2019-01-11	ALPRAZOLAM	TAB	0.5 MG	90	Respondent
2019-02-02	METHADONE HCL	TAB	5 MG	90	Respondent
2019-02-05	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2019-02-08	ALPRAZOLAM	TAB	0.5 MG	90	Respondent
2019-03-04	METHADONE HCL	TAB	5 MG	90	Respondent
2019-03-07	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2019-03-11	ALPRAZOLAM	TAB	0.5 MG	90	Respondent
2019-04-02	METHADONE HCL	TAB	5 MG	90	Respondent
2019-04-04	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2019-04-09	ALPRAZOLAM	TAB	0.5 MG	90	Respondent
2019-05-02	METHADONE HCL	TAB	5 MG	90	Respondent
2019-05-02	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2019-05-09	ALPRAZOLAM	TAB	0.5 MG	90	Respondent
2019-05-31	METHADONE HCL	TAB	5 MG	90	Respondent
2019-06-03	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2019-06-07	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2019-07-01	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2019-07-01	METHADONE HCL	TAB	5 MG	90	Respondent
2019-07-09	ALPRAZOLAM	TAB	0.5 MG	60	Respondent
2019-07-29	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent

Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2019-07-30	METHADONE HCL	TAB	5 MG	75	Respondent
2019-08-08	ALPRAZOLAM	TAB	0.25 MG	60	Respondent
2019-08-30	ALPRAZOLAM	TAB	0.5 MG	40	R.S.
2019-09-04	METHADONE HCL	TAB	5 MG	60	Respondent
2019-09-04	ZOLPIDEM TARTRATE	TAB	10 MG	30	A.P.
2019-10-04	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2019-10-07	METHADONE HCL	TAB	5 MG	60	Respondent
2019-10-18	ALPRAZOLAM	TAB	0.5 MG	40	Respondent
2019-11-05	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent
2019-11-11	METHADONE HCL	TAB	5 MG	23	Respondent
2019-11-21	ALPRAZOLAM	TAB	0.5 MG	40	Respondent
2019-12-03	ZOLPIDEM TARTRATE	TAB	10 MG	30	Respondent

48. On or about May 23, 2019, Respondent participated in an interview with investigators working on behalf of the Board, in which he stated that he referred Patient A to a psychiatrist on more than one occasion, but Patient A never attended the appointments. Respondent admitted that he did not document the psychiatric referrals in the medical records for Patient A. Respondent stated that he examined Patient A's back at each visit, but did not document the back examinations in the medical records. Respondent admitted that he did not perform any urine testing on Patient A while prescribing controlled substances. Respondent stated that he needs to implement and apply the Board's pain management guidelines more thoroughly in the care of his patients, and that he needs "to document physical findings and other things more thoroughly in [the] record." Respondent stated that Patient A had been stable on a prescription of "60 morphine equivalents per day...for five years" but that he needed to "try to taper that again."

**CIRCUMSTANCES RELATED TO PATIENT B**

2007-2012

49. On or about July 17, 2007, Patient B first presented to Respondent for a B12 injection at 58 years old. Patient returned to Respondent for appointments approximately fifteen times from 2007 through 2012. The chief complaints at these visits were varied, including B12 injections, influenza immunizations, urgent care visits, cellulitis of the left foot, and a boil.

50. On or about August 29, 2010, Patient B's current medications included Flexeril, and Vicodin 5mg/500mg.



1 records for these visits do not include a list of current medications. Respondent did not document  
2 providing informed consent to Patient B related to the risks and benefits of taking controlled  
3 substances.

4 2015

5 54. Patient B returned to Respondent for appointments approximately ten times in 2015,  
6 on a monthly basis. The chief complaints at these visits were identical at each visit, identifying  
7 her current age, at times inaccurately, and that she was returning for a B12 injection.

8 55. On or about August 31, 2015, Respondent documented an examination of Patient B's  
9 complaint of low back pain. Respondent documented a nonfocal neurological examination, but  
10 did not document objectives such as pain relief and/or improved physical and psychosocial  
11 function, by which the effectiveness of a treatment plan could be evaluated. Respondent did not  
12 indicate if any additional diagnostic evaluations or other non-opiate treatment was indicated or  
13 planned in the care of Patient B. Respondent listed low back pain as under the assessment, and  
14 the plan was to provide refills of Norco. Respondent did not document providing informed  
15 consent to Patient B related to the risks and benefits of taking controlled substances.

16 56. On or about March 19, 2015, Patient B's current medication list included Paxil, and  
17 Norco.

18 57. On or about September 24, 2015, Patient B's current medication list included Paxil,  
19 Soma, and Norco.

20 58. On or about December 28, 2015, Patient B filled the following prescriptions for  
21 controlled substances:

22

Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2015-12-28	CARISOPRODOL	TAB	350 MG	60	Respondent

23  
24

25 2016

26 59. Patient B returned to Respondent for appointments approximately seven times in  
27 2016. The chief complaints at these visits varied, including UTI symptoms, an urgent care visit,  
28 B12 injections, and follow-up visits.

1           60. On or about January 14, 2016, Patient B returned to Respondent at the urgent care  
2 complaining of symptoms consistent with a urinary tract infection. Despite continuing to  
3 prescribe Norco to Patient B, the plan does not document a prescription for Norco.

4           61. On or about March 31, 2016, Patient B presented to Respondent for a follow up visit  
5 related to her middle and lower lumbar spine pain. Respondent noted that she was negative for  
6 depression, and documented a nonfocal neurologic examination. Respondent documented that  
7 the neurovascular examination revealed deep tendon reflexes at 2/4 in the Achilles and patella  
8 bilaterally. Respondent indicated that Patient B was negative for the straight leg raise test.  
9 Respondent did not document objectives such as pain relief and/or improved physical and  
10 psychosocial function, by which the effectiveness of a treatment plan could be evaluated.  
11 Respondent did not indicate if any additional diagnostic evaluations or other non-opiate treatment  
12 was indicated or planned in the care of Patient B. Despite continuing to prescribe Norco and  
13 prescribing oxycodone to Patient B, the plan does not document these prescriptions in the medical  
14 records related to this visit.

15           62. On or about June 21, 2016, Patient B presented to Respondent's office for a B12  
16 injection at 57 years of age. Respondent did not document a periodic review of the course of  
17 treatment of Patient B, and any new information about the etiology of her state of health related to  
18 her pain complaint.

19           63. On or about September 1, 2016, Respondent performed a limited history and physical  
20 on Patient B. Respondent performed a psychological screening that included a limited substance  
21 abuse history. Respondent did not document a full patient history and physical. Respondent did  
22 not document Patient B's prior pain treatments, physical function, or a medical diagnosis related  
23 to the prescription of opiate medications. Respondent did not document objective information  
24 such as pain relief and/or improved physical and psychosocial function, by which the  
25 effectiveness of a treatment plan could be evaluated. Respondent did not indicate if any  
26 additional diagnostic evaluations or other non-opiate treatments were indicated or planned for  
27 Patient B. Respondent did not document a periodic review of the course of treatment of Patient  
28 B, and any new information about the etiology of her state of health related to her pain complaint.



1 Respondent diagnosed Patient B with chronic low back pain, and the plan was to refill her  
 2 prescription of Norco.

3 64. During the period on or about January 14, 2016, through on or about December 20,  
 4 2016, Patient B filled the following prescriptions for controlled substances:

Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2016-01-14	HYDROCODONE BITARTRATE- ACETAMINOPHEN	TAB	325 MG-7.5 MG	50	K.K.
2016-01-26	CARISOPRODOL	TAB	350 MG	60	Respondent
2016-02-25	CARISOPRODOL	TAB	350 MG	60	Respondent
2016-02-29	HYDROCODONE BITARTRATE- ACETAMINOPHEN	TAB	325 MG-7.5 MG	50	Respondent
2016-03-23	ACETAMINOPHEN-HYDROCODONE BITARTRATE	TAB	325 MG-5 MG	36	N.A.
2016-03-23	CARISOPRODOL	TAB	350 MG	60	Respondent
2016-04-01	OXYCODONE HCL- ACETAMINOPHEN	TAB	325 MG-5 MG	60	Respondent
2016-04-01	TRAMADOL HCL	TAB	50 MG	9	J.O.
2016-04-24	CARISOPRODOL	TAB	350 MG	60	Respondent
2016-05-01	OXYCODONE HCL- ACETAMINOPHEN	TAB	325 MG-5 MG	60	Respondent
2016-05-23	CARISOPRODOL	TAB	350 MG	60	Respondent
2016-06-21	CARISOPRODOL	TAB	350 MG	60	Respondent
2016-06-21	OXYCODONE HCL- ACETAMINOPHEN	TAB	325 MG-5 MG	60	Respondent
2016-07-19	CARISOPRODOL	TAB	350 MG	60	Respondent
2016-08-15	CARISOPRODOL	TAB	350 MG	60	Respondent
2016-09-01	HYDROCODONE BITARTRATE- ACETAMINOPHEN	TAB	325 MG-7.5 MG	60	Respondent
2016-09-13	CARISOPRODOL	TAB	350 MG	60	Respondent
2016-10-01	HYDROCODONE BITARTRATE- ACETAMINOPHEN	TAB	325 MG-7.5 MG	60	Respondent
2016-10-11	CARISOPRODOL	TAB	350 MG	60	Respondent
2016-11-02	HYDROCODONE BITARTRATE- ACETAMINOPHEN	TAB	325 MG-7.5 MG	60	Respondent
2016-11-13	CARISOPRODOL	TAB	350 MG	60	Respondent
2016-11-22	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	60	Respondent
2016-12-12	CARISOPRODOL	TAB	350 MG	60	Respondent
2016-12-20	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	60	Respondent

27 ///

2017

65. Patient B returned to Respondent for appointments approximately four times in 2017, on or about April 20, May 17, June 30, and October 5, 2017. The history of presenting illness at these visits were identical at each visit, stating that she was there for a B12 injection. Respondent did not document providing informed consent to Patient B related to the risks and benefits of taking controlled substances.

66. During the period on or about January 9, 2017, through on or about December 19, 2017, Patient B filled the following prescriptions for controlled substances:

Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2017-01-09	CARISOPRODOL	TAB	350 MG	60	Respondent
2017-01-19	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	60	Respondent
2017-02-07	CARISOPRODOL	TAB	350 MG	60	Respondent
2017-02-20	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	60	Respondent
2017-03-12	CARISOPRODOL	TAB	350 MG	60	Respondent
2017-03-22	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent
2017-04-12	CARISOPRODOL	TAB	350 MG	60	Respondent
2017-04-23	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent
2017-05-18	CARISOPRODOL	TAB	350 MG	60	Respondent
2017-05-26	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent
2017-07-18	CARISOPRODOL	TAB	350 MG	60	Respondent
2017-07-23	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	J.K.
2017-08-18	CARISOPRODOL	TAB	350 MG	60	Respondent
2017-08-22	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent
2017-09-19	CARISOPRODOL	TAB	350 MG	60	Respondent
2017-09-27	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent
2017-10-17	CARISOPRODOL	TAB	350 MG	60	Respondent
2017-10-27	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent
2017-11-16	CARISOPRODOL	TAB	350 MG	60	Respondent
2017-12-19	CARISOPRODOL	TAB	350 MG	60	Respondent

\\

2018

67. During the period on or about January 2, 2018, through on or about December 5, 2018, Patient B filled the following prescriptions for controlled substances:

Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2018-01-02	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent
2018-01-18	CARISOPRODOL	TAB	350 MG	60	Respondent
2018-02-04	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent
2018-02-27	CARISOPRODOL	TAB	350 MG	60	Respondent
2018-03-03	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent
2018-03-26	CARISOPRODOL	TAB	350 MG	60	Respondent
2018-04-03	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent
2018-04-27	CARISOPRODOL	TAB	350 MG	60	Respondent
2018-05-06	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent
2018-05-29	CARISOPRODOL	TAB	350 MG	60	Respondent
2018-06-05	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent
2018-06-29	CARISOPRODOL	TAB	350 MG	60	Respondent
2018-07-06	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent
2018-07-29	CARISOPRODOL	TAB	350 MG	60	Respondent
2018-08-05	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent
2018-08-28	CARISOPRODOL	TAB	350 MG	60	Respondent
2018-09-05	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent
2018-10-02	CARISOPRODOL	TAB	350 MG	60	Respondent
2018-10-05	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent
2018-11-02	CARISOPRODOL	TAB	350 MG	60	Respondent
2018-11-04	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent
2018-12-03	CARISOPRODOL	TAB	350 MG	60	Respondent
2018-12-05	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent

\\

\\

\\

2019

68. On or about May 23, 2019, Respondent participated in an interview with investigators working on behalf of the Board. Respondent admitted that he didn't routinely review CURES reports in the care and treatment of Patient B while she was prescribed controlled substances. Respondent stated that he was not seeing Patient B as often as he should have while prescribing controlled substances.

69. During the period on or about January 3, 2019, through on or about December 20, 2019, Patient B filled the following prescriptions for controlled substances:

Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2019-01-03	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent
2019-01-03	CARISOPRODOL	TAB	350 MG	60	Respondent
2019-02-02	CARISOPRODOL	TAB	350 MG	60	Respondent
2019-02-03	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	70	Respondent
2019-03-04	CARISOPRODOL	TAB	350 MG	60	Respondent
2019-03-20	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	60	Respondent
2019-04-07	CARISOPRODOL	TAB	350 MG	60	Respondent
2019-04-23	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-60 MG	60	Respondent
2019-05-07	CARISOPRODOL	TAB	350 MG	60	J.K.
2019-05-23	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-30 MG	50	Respondent
2019-06-04	CARISOPRODOL	TAB	350 MG	30	Respondent
2019-06-20	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-30 MG	30	Respondent
2019-07-23	ACETAMINOPHEN-HYDROCODONE BITARTRATE	TAB	325 MG-5 MG	12	V.F.
2019-07-26	ACETAMINOPHEN-HYDROCODONE BITARTRATE	TAB	325 MG-5 MG	6	B.R.
2019-11-20	ACETAMINOPHEN-CODEINE PHOSPHATE	TAB	300 MG-30 MG	10	M.P.
2019-12-20	CARISOPRODOL	TAB	350 MG	30	C.D.

\\  
\\  
\\  
\\

1 CIRCUMSTANCES RELATED TO PATIENT C

2 2013

3 70. On or about March 6, 2013, Patient C first presented to Respondent's clinic at 59  
4 years old, complaining of lower back pain. Patient C's history included a motor vehicle accident,  
5 spinal fractures, spinal fusion surgery, lumbar decompression surgery, and he was taking  
6 controlled substances prescribed by his prior physician. Patient C was currently taking  
7 Neurontin, aspirin, baclofen, oxycodone HCl, Oxycontin, and Valium. Respondent's plan for  
8 Patient C was to continue his current medication regimen without change, return in one month for  
9 a follow up visit, and to "taper oxycodone as tolerated."

10 71. Patient C returned to Respondent for appointments approximately nine times in 2013.  
11 The chief complaint for each visit varied, including follow up visits, and urgent care visits.

12 2014

13 72. Patient C returned to Respondent for appointments approximately eight times in  
14 2014. The chief complaint for each visit varied, including follow up visits, urgent care visits, and  
15 a preoperative clearance examination.

16 73. On or about March 6, 2014, Patient C's current medications included baclofen,  
17 Valium, gabapentin, oxycodone, OxyContin, acetaminophen, and aspirin.

18 2015

19 74. Patient C returned to Respondent for appointments approximately eleven times in  
20 2015. The chief complaint for each visit varied, including follow up visits, contusions, abdominal  
21 pain, immunizations, lesions, rib pain, and urgent care visits.

22 75. On or about October 14, 2015, Patient C's current medications included baclofen,  
23 gabapentin, oxycodone, OxyContin, acetaminophen, Cymbalta and aspirin.

24 2016

25 76. Patient C returned to Respondent for appointments approximately nine times in 2016.  
26 The chief complaint for each visit varied, including follow up visits, lesions, leg swelling, rib  
27 pain, emergency room discharge follow-up, urgent care visits, and on occasion the chief  
28 complaint only stated his age, and identified him as a white male.

1 77. During the period on or about January 2, 2016, through on or about December 12,  
2 2016, Patient C filled the following prescriptions for controlled substances:

Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2016-01-02	OXYCODONE HCL	TAB	10 MG	150	Respondent
2016-01-04	OXYCONTIN	TER	20 MG	180	Respondent
2016-02-03	OXYCODONE HCL	TAB	10 MG	150	Respondent
2016-02-03	OXYCONTIN	TER	20 MG	180	Respondent
2016-03-04	OXYCODONE HCL	TER	20 MG	180	Respondent
2016-03-04	OXYCODONE HCL	TAB	10 MG	150	Respondent
2016-04-06	OXYCODONE HCL	TER	20 MG	180	Respondent
2016-04-06	OXYCODONE HCL	TAB	10 MG	150	Respondent
2016-05-05	OXYCODONE HCL	TAB	10 MG	150	Respondent
2016-05-05	OXYCODONE HCL	TER	20 MG	150	Respondent
2016-06-06	OXYCODONE HCL	TER	20 MG	150	Respondent
2016-06-06	OXYCODONE HCL	TAB	10 MG	150	Respondent
2016-07-19	OXYCODONE HCL	TAB	10 MG	150	Respondent
2016-07-29	OXYCODONE HCL	TER	20 MG	150	Respondent
2016-08-30	OXYCODONE HCL	TER	20 MG	90	Respondent
2016-09-02	OXYCODONE HCL	TAB	10 MG	90	Respondent
2016-10-03	OXYCODONE HCL	TER	20 MG	90	Respondent
2016-10-11	OXYCODONE HCL	TAB	10 MG	90	Respondent
2016-11-09	OXYCODONE HCL	TER	20 MG	90	Respondent
2016-12-12	OXYCODONE HCL	TER	20 MG	90	Respondent

17 2017

18 78. Patient C returned to Respondent for appointments approximately six times in 2017.  
19 The chief complaint for each visit varied, including follow up visits, requests for refills of  
20 oxycodone and OxyContin, and a list of his existing health problems placed under the chief  
21 complaint heading.

22 79. On or about August 21, 2017, Patient C presented to Respondent for a follow-up visit.  
23 Respondent noted that Patient C's pain was stable, but he wanted refills of his pain medications.  
24 The plan simply stated, "oxycontin and oxycodone rf x3."

25 80. On or about October 2, 2017, Respondent added an addendum to the August 21, 2017  
26 chart note. The addendum included a more thorough treatment plan and objectives for Patient  
27 C's low back pain. Respondent stated that he discussed with Patient C that "opioids cause  
28 dependence and tolerance and can cause respiratory depression or death." Respondent did not

1 document any discussion of the potential benefits and other risks associated with opiates,  
 2 including the potential negative effects on his kidney, liver and testosterone levels. Respondent  
 3 did not sufficiently document the discussion of informed consent to adequately inform Patient C  
 4 of the risks associated with using opiates. Respondent provided Patient C a referral for further  
 5 diagnostic evaluation by a neurologist, but did not recommend any alternative treatment  
 6 modalities for his pain other than the continued use of controlled substances.

7 81. During the period on or about January 10, 2017, through on or about December 5,  
 8 2017, Patient C filled the following prescriptions for controlled substances:

Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2017-01-10	OXYCODONE HCL	TAB	10 MG	60	A.P.
2017-01-10	OXYCONTIN	TER	20 MG	90	A.P.
2017-02-14	OXYCONTIN	TER	20 MG	90	Respondent
2017-03-17	OXYCONTIN	TER	20 MG	90	Respondent
2017-04-18	OXYCONTIN	TER	20 MG	90	Respondent
2017-05-16	OXYCODONE HCL	TAB	10 MG	60	Respondent
2017-05-17	OXYCONTIN	TER	20 MG	90	Respondent
2017-06-15	OXYCODONE HCL	TAB	10 MG	60	Respondent
2017-06-16	OXYCODONE HCL	TER	20 MG	90	Respondent
2017-07-17	OXYCODONE HCL	TAB	10 MG	60	Respondent
2017-07-17	OXYCODONE HCL	TER	20 MG	90	Respondent
2017-08-14	OXYCODONE HCL	TAB	10 MG	150	Respondent
2017-08-15	OXYCODONE HCL	TER	20 MG	120	Respondent
2017-09-20	OXYCODONE HCL	TER	20 MG	120	Respondent
2017-09-20	OXYCODONE HCL	TAB	10 MG	120	Respondent
2017-10-24	OXYCODONE HCL	TER	20 MG	120	Respondent
2017-10-24	OXYCODONE HCL	TAB	10 MG	120	Respondent
2017-12-05	OXYCODONE HCL	TAB	10 MG	60	Respondent
2017-12-05	OXYCONTIN	TER	20 MG	120	Respondent

22 2018

23 82. During the period on or about January 3, 2018, through on or about December 22,  
 24 2018, Patient C filled the following prescriptions for controlled substances:

Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2018-01-03	OXYCODONE HCL	TAB	10 MG	60	Respondent
2018-01-03	OXYCODONE HCL	TER	20 MG	120	Respondent
2018-02-04	OXYCODONE HCL	TAB	10 MG	60	Respondent
2018-02-04	OXYCONTIN	TER	20 MG	120	Respondent
2018-03-10	OXYCODONE HCL	TAB	10 MG	60	Respondent

Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2018-03-14	OXYCONTIN	TER	20 MG	120	Respondent
2018-04-15	OXYCODONE HCL	TAB	10 MG	75	Respondent
2018-04-15	OXYCONTIN	TER	20 MG	90	Respondent
2018-04-30	LORAZEPAM	TAB	1 MG	2	J.K.
2018-05-13	OXYCODONE HCL	TAB	10 MG	75	Respondent
2018-05-14	OXYCONTIN	TER	20 MG	90	Respondent
2018-06-18	OXYCODONE HCL	TAB	10 MG	75	Respondent
2018-06-21	OXYCONTIN	TER	20 MG	90	Respondent
2018-07-21	OXYCODONE HCL	TAB	10 MG	90	Respondent
2018-07-21	OXYCONTIN	TER	20 MG	90	Respondent
2018-08-20	OXYCODONE HCL	TAB	10 MG	90	J.M.
2018-08-20	OXYCONTIN	TER	20 MG	90	J.M.
2018-09-23	OXYCODONE HCL	TER	20 MG	90	Respondent
2018-09-23	OXYCODONE HCL	TAB	10 MG	90	Respondent
2018-10-23	OXYCODONE HCL	TER	20 MG	90	Respondent
2018-10-23	OXYCODONE HCL	TAB	10 MG	90	Respondent
2018-11-22	OXYCODONE HCL	TAB	10 MG	90	Respondent
2018-11-22	OXYCODONE HCL	TER	20 MG	90	Respondent
2018-12-22	OXYCODONE HCL	TAB	10 MG	90	Respondent
2018-12-22	OXYCODONE HCL	TER	20 MG	90	Respondent

2019

83. During the period on or about January 21, 2019, through on or about December 19, 2019, Patient C filled the following prescriptions for controlled substances:

Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2019-01-21	OXYCODONE HCL	TER	20 MG	60	Respondent
2019-01-21	OXYCODONE HCL-ACETAMINOPHEN	TAB	325 MG-10 MG	120	Respondent
2019-03-01	OXYCODONE HCL - ACETAMINOPHEN	TAB	325 MG-10 MG	90	Respondent
2019-03-01	OXYCONTIN	TER	20 MG	60	Respondent
2019-03-31	OXYCODONE HCL	TER	10 MG	90	Respondent
2019-03-31	OXYCODONE HCL-ACETAMINOPHEN	TAB	325 MG-10 MG	90	Respondent
2019-04-30	OXYCODONE HCL-ACETAMINOPHEN	TAB	325 MG-10 MG	90	Respondent
2019-04-30	OXYCONTIN	TER	10 MG	90	Respondent
2019-05-31	OXYCODONE HCL-ACETAMINOPHEN	TAB	325 MG-10 MG	90	Respondent
2019-05-31	OXYCONTIN	TER	10 MG	90	Respondent
2019-07-01	OXYCONTIN	TER	10 MG	60	Respondent
2019-07-03	OXYCODONE HCL-ACETAMINOPHEN	TAB	325 MG-7.5 MG	90	Respondent



Date Filled	Drug Name	Form	Drug Strength	Qty	Prescriber Name
2019-08-01	OXYCODONE HCL-ACETAMINOPHEN	TAB	325 MG-10 MG	90	Respondent
2019-08-01	OXYCONTIN	TER	10 MG	60	Respondent
2019-08-17	OXYCODONE HCL	TAB	15 MG	30	A.H.
2019-09-04	OXYCODONE HCL-ACETAMINOPHEN	TAB	325 MG-5 MG	60	J.R.
2019-09-04	OXYCONTIN	TER	10 MG	67	J.R.
2019-10-03	OXYCODONE HCL	TAB	5 MG	135	Respondent
2019-11-02	OXYCODONE HCL	TAB	5 MG	75	Respondent

84. On or about May 23, 2019, Respondent participated in an interview with investigators working on behalf of the Board. Respondent admitted that he did not utilize pain management agreements or urine drug testing with Patient C, but has implemented both measures after learning of the Board's investigation and prior to his interview.

**FIRST CAUSE FOR DISCIPLINE**

**(Gross Negligence)**

85. Respondent's Physician's and Surgeon's Certificate License No. G 48964 is subject to disciplinary action under section 2227, as defined by section 2234, subdivision (b), in that he committed act(s) and/or omission(s) constituting gross negligence. The factual circumstances set forth above relating to Patient A and Patient B in paragraphs 28 through 69 are hereby incorporated by reference as if set forth fully herein.

**PATIENT A**

86. Respondent did not document an adequate treatment plan that included objectives by which the treatment plan could be evaluated related to Patient A's use of opiate medications. Respondent did not utilize or document the consideration of multiple non-opiate treatment modalities and/or rehabilitation as alternatives to Patient A's continued use of opiate medications. Respondent failed to document an adequate treatment plan and objectives for Patient A related to Patient A's use of opiate medications. Each such failure constitutes gross negligence.

87. Respondent did not provide and/or document informed consent for Patient A related to the benefits and risks of controlled substances prior to prescribing controlled substances, which constitutes gross negligence.

///

1           88. Respondent did not document an adequate history and physical for Patient A. On  
2 some visits, Respondent continued to prescribe controlled substances to Patient A without  
3 documenting an adequate history and physical related to Patient A's lower back pain.  
4 Respondent repeatedly failed to document an assessment of Patient A's pain, an assessment of  
5 any underlying or coexisting diseases or conditions, Patient A's history of prior pain treatment, or  
6 documentation of the presence of a medical condition that indicated the continued use of  
7 controlled substances. Respondent failed to document a physical examination utilizing both  
8 subjective and objective components to support the diagnosis of low back pain. Respondent did  
9 not document positive and negative physical examination findings related to Patient A's low back  
10 pain, which could have identified and/or ruled out potential causes for Patient A's continued low  
11 back pain. Respondent failed to document an adequate physical examination to support the  
12 prescription and continued use of opiates to treat Patient A's low back pain. Respondent failed to  
13 perform and/or document an adequate medical history and physical examination for Patient A.  
14 Each such failure constitutes gross negligence.

15           89. Despite routine patient encounters with Patient A approximately every three months,  
16 Respondent did not document adequate evaluation of Patient A's progress while using controlled  
17 substances. The documentation for Patient A's follow up visits was typically cursory, and  
18 sometimes contained no more than documentation of Patient A's vital signs. Respondent failed to  
19 adequately document new information regarding the etiology of Patient A's pain, or the state of  
20 his health at follow-up visits. Respondent did not include pertinent positive and negative findings  
21 in physical examinations, which could have aided in a review of Patient A's progression and  
22 current functional status, and lead to a more specific diagnosis of Patient A's pain. Respondent  
23 failed to assess the appropriateness of the continued use of opiates in the treatment plan for  
24 Patient A, and failed to document consideration of other non-opiate treatment modalities.  
25 Respondent did not document and/or perform an adequate periodic review of Patient A's plan of  
26 care while prescribing controlled substances. Each such failure constitutes gross negligence.

27           90. Despite ordering a single urine drug screen, Respondent did not document and/or  
28 obtain any other consultations or studies for Patient A. Respondent did not order any referrals to

1 specialists or obtain imaging studies to obtain a more specific diagnosis of Patient A's lower back  
2 pain. Respondent did not refer and/or document consideration of referring Patient A to a pain  
3 management specialist. Respondent did not offer Patient A consultations for supervised physical  
4 therapy, chiropractic care, home exercise, injections, or a pain psychologist. Respondent did not  
5 seek appropriate consultations while prescribing controlled substances to Patient A. Each such  
6 failure constitutes gross negligence.

7 91. Respondent did not adequately document a treatment plan and objectives related to  
8 the care of Patient A. Respondent failed to maintain adequate and complete medical records  
9 relating to the medical history and physical examination, evaluations and consultations, treatment  
10 plan and objectives, informed consent, treatments, medicals, rationale for changes in the  
11 treatment plan or medications, agreements with the patient, and periodic reviews of Patient A's  
12 treatment plan. Respondent failed to document an informed consent for the use of opiate  
13 medications prior to initiating opiate therapy. Respondent failed to document an informed  
14 consent, and periodically review it with Patient A while prescribing opiates. Respondent  
15 commonly documented the opiate medications prescribed to Patient A, absent any further  
16 explanation of why he chose to continue opiate therapy. Respondent failed to maintain adequate  
17 medical records in the care and treatment of Patient A. Each such failure constitutes gross  
18 negligence.

19 **PATIENT B**

20 92. Respondent did not document an adequate medical history and physical examination  
21 for Patient B prior to prescribing controlled substances. Despite documenting a limited history  
22 and physical on or about September 1, 2016, Respondent did not document an adequate history  
23 for Patient B related to the prescription of controlled substances. Respondent did not document  
24 Patient B's prior pain treatments, response to prior pain treatments, physical function, or  
25 document a medical diagnosis that required the prescription of opiate medications. Respondent  
26 failed to document an adequate medical history and physical examination for Patient B. Each  
27 such failure constitutes gross negligence.

28 ///

1           93. Respondent did not document any consultations or follow up by other providers  
2 related to Patient B's complaint of low back pain. Respondent documented that Patient B  
3 previously visited a neurosurgeon, but failed to seek a reevaluation or reassessment of Patient B  
4 by the neurosurgeon in light of his continued prescriptions for controlled substances. Respondent  
5 did not refer patient B to a pain management specialist or other professionals in order to address  
6 her pain, and address her treatment goals. Respondent failed to adequately seek consultations and  
7 evaluations for Patient B related to her pain. Each such failure constitutes gross negligence.

8           94. Respondent's treatment plan for Patient B was commonly limited to a note that the  
9 medications would be refilled. Respondent did not document objectives such as pain relief and/or  
10 improved physical and psychosocial function, by which the effectiveness of a treatment plan  
11 could be evaluated. Respondent did not indicate if any additional diagnostic evaluations or other  
12 non-opiate treatment was indicated or planned in the care of Patient B. Respondent failed to  
13 adequately document a treatment plan and objectives related to the prescription of opiate  
14 medications in the care and treatment of Patient B. Each such failure constitutes gross  
15 negligence.

16           95. Respondent did not document adequate evaluation of Patient B's progress while using  
17 controlled substances. Respondent failed to adequately document new information regarding the  
18 etiology of Patient A's pain, or the state of her health at follow-up visits. Respondent did not  
19 include pertinent positive and negative findings in physical examinations, which could have aided  
20 in a review of Patient B's progression and current functional status, and lead to a more specific  
21 diagnosis of Patient B's pain. Respondent failed to assess the appropriateness of the continued  
22 use of opiates in the treatment plan for Patient B, and failed to document consideration of other  
23 non-opiate treatment modalities. Respondent did not document and/or perform an adequate  
24 periodic review of Patient B's plan of care while prescribing controlled substances. Each such  
25 failure constitutes gross negligence.

26           96. Respondent did not obtain and/or document providing informed consent to Patient B  
27 prior to prescribing controlled substances. Respondent's medical records for Patient B contain no  
28 documentation of a discussion that includes the risks and benefits of using controlled substances

1 or other treatment modalities with Patient B. Respondent failed to provide and/or document  
2 providing informed consent to Patient B. Each such failure constitutes gross negligence.

3 97. Respondent failed to maintain adequate and complete medical records relating to the  
4 medical history and physical examination, evaluations and consultations, treatment plan and  
5 objectives, informed consent, treatments, medical rationale for changes in the treatment plan or  
6 medications, agreements with the patient, and periodic reviews of Patient B's treatment plan.  
7 Respondent failed to document an informed consent for the use of opiate medications prior to  
8 initiating opiate therapy. Respondent failed to document an informed consent, and periodically  
9 review it with Patient B while prescribing opiates. Respondent provided follow-up care to Patient  
10 B on numerous occasions, without documenting the additional care provided in the medical  
11 records. Respondent prescribed oxycodone and Norco to Patient B in 2016, but failed to  
12 document the prescriptions in her medical records. Respondent failed to maintain adequate  
13 medical records in the care and treatment of Patient B. Each such failure constitutes gross  
14 negligence.

15 **SECOND CAUSE FOR DISCIPLINE**

16 **(Repeated Negligent Acts)**

17 98. Respondent has subjected his Physician's and Surgeon's Certificate License No. G  
18 48964 to disciplinary action under section 2227, as defined by section 2234, subdivision (c), of  
19 the Code, in that he committed multiple acts and/or omissions constituting negligence. The  
20 circumstances are set forth in Paragraphs 28 through 84, which are hereby incorporated by  
21 reference as if fully set forth herein.

22 **PATIENT C**

23 99. Respondent did not adequately document a treatment plan for Patient C related to the  
24 use of opiate medications. Despite documenting a limited treatment plan on or about August 17,  
25 2017, Respondent did not provide alternative non-opiate treatment modalities including physical  
26 therapy to Patient C. Respondent failed to provide and/or document an adequate treatment plan  
27 in the care and treatment of Patient C. Each such failure constitutes negligence.

28



PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Medical Board of California issue a decision:

1. Revoking or suspending Physician's and Surgeon's Certificate License No. G 48964, issued to James Clyde Maclaren, Jr., M.D.;


2. Revoking, suspending or denying approval of James Clyde Maclaren, Jr., M.D.'s authority to supervise physician assistants and advanced practice nurses;

3. Ordering James Clyde Maclaren, Jr., M.D., if placed on probation, to pay the Board the costs of probation monitoring; and

4. Taking such other and further action as deemed necessary and proper.

JAN 23 2020

DATED: \_\_\_\_\_



CHRISTINE J. LALLY  
Interim Executive Director  
Medical Board of California  
Department of Consumer Affairs  
State of California  
*Complainant*

FR2019300834  
95331335.docx